Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Ovarian Cancer|Gynecological Cancer|Head and Neck Carcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Non-squamous Cell Lung Cancer
Interventions: DRUG: PM01183 + paclitaxel +/- bevacizumab
Sponsor: PharmaMar